With a therapy that could improve and save the lives of millions, we’re backing a VCU School of Pharmacy researcher with a novel and promising treatment for sickle cell disease. Clinical trials for the treatment, licensed to a VCU-born startup, are tentatively slated to start in 2022 in England.

Read the full story here.